Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bruce L Innis

Showing results (101-110 of 119) with videos related to

Pageof 12
Sort By:
Vaccine|July 12, 2005
An evaluation of dengue type-2 inactivated, recombinant subunit, and live-attenuated vaccine candidates in the rhesus macaque modelJ Robert Putnak, Beth-Ann Coller, Gerald Voss, et al.
Influenza and Other Respiratory Viruses|April 8, 2014
Influenza symptoms and their impact on elderly adults: randomised trial of AS03-adjuvanted or non-adjuvanted inactivated trivalent seasonal influenza vaccinesGerrit A van Essen, Jiri Beran, Jeanne-Marie Devaster, et al.
The Pediatric Infectious Disease Journal|October 17, 2018
Anamnestic Immune Response and Safety of an Inactivated Quadrivalent Influenza Vaccine in Primed Versus Vaccine-Naïve ChildrenCarine Claeys, Vijayalakshmi Chandrasekaran, José García-Sicilia, et al.
The New England Journal of Medicine|December 17, 2013
Vaccine for prevention of mild and moderate-to-severe influenza in childrenVarsha K Jain, Luis Rivera, Khalequ Zaman, et al.
The Journal of Infectious Diseases|July 13, 2013
Immunogenicity and safety of an inactivated quadrivalent influenza vaccine candidate: a phase III randomized controlled trial in childrenJoanne M Langley, Alfonso Carmona Martinez, Archana Chatterjee, et al.
Nature Communications|October 28, 2021
A Newcastle disease virus expressing a stabilized spike protein of SARS-CoV-2 induces protective immune responsesWeina Sun, Yonghong Liu, Fatima Amanat, et al.
The Lancet. Infectious Diseases|March 23, 2013
AS03-adjuvanted versus non-adjuvanted inactivated trivalent influenza vaccine against seasonal influenza in elderly people: a phase 3 randomised trialJanet E McElhaney, Jiri Beran, Jeanne-Marie Devaster, et al.
Vaccine|January 25, 2020
Does respiratory syncytial virus lower respiratory illness in early life cause recurrent wheeze of early childhood and asthma? Critical review of the evidence and guidance for future studies from a World Health Organization-sponsored meetingAmanda J Driscoll, S Hasan Arshad, Louis Bont, et al.
The Journal of Infectious Diseases|March 22, 2014
Relative efficacy of AS03-adjuvanted pandemic influenza A(H1N1) vaccine in children: results of a controlled, randomized efficacy trialTerry Nolan, Sumita Roy-Ghanta, May Montellano, et al.
Lancet (London, England)|November 17, 2025
Safety and immunogenicity of a Nipah virus vaccine (HeV-sG-V) in adults: a single-centre, randomised, observer-blind, placebo-controlled, phase 1 studyRobert W Frenck, Abdi Naficy, Jodi Feser, et al.
Pageof 12

Showing results (101-110 of 119) with videos related to

Sort By:
Pageof 12
Vaccine|July 12, 2005
An evaluation of dengue type-2 inactivated, recombinant subunit, and live-attenuated vaccine candidates in the rhesus macaque modelJ Robert Putnak, Beth-Ann Coller, Gerald Voss, et al.
Influenza and Other Respiratory Viruses|April 8, 2014
Influenza symptoms and their impact on elderly adults: randomised trial of AS03-adjuvanted or non-adjuvanted inactivated trivalent seasonal influenza vaccinesGerrit A van Essen, Jiri Beran, Jeanne-Marie Devaster, et al.
The Pediatric Infectious Disease Journal|October 17, 2018
Anamnestic Immune Response and Safety of an Inactivated Quadrivalent Influenza Vaccine in Primed Versus Vaccine-Naïve ChildrenCarine Claeys, Vijayalakshmi Chandrasekaran, José García-Sicilia, et al.
The New England Journal of Medicine|December 17, 2013
Vaccine for prevention of mild and moderate-to-severe influenza in childrenVarsha K Jain, Luis Rivera, Khalequ Zaman, et al.
The Journal of Infectious Diseases|July 13, 2013
Immunogenicity and safety of an inactivated quadrivalent influenza vaccine candidate: a phase III randomized controlled trial in childrenJoanne M Langley, Alfonso Carmona Martinez, Archana Chatterjee, et al.
Nature Communications|October 28, 2021
A Newcastle disease virus expressing a stabilized spike protein of SARS-CoV-2 induces protective immune responsesWeina Sun, Yonghong Liu, Fatima Amanat, et al.
The Lancet. Infectious Diseases|March 23, 2013
AS03-adjuvanted versus non-adjuvanted inactivated trivalent influenza vaccine against seasonal influenza in elderly people: a phase 3 randomised trialJanet E McElhaney, Jiri Beran, Jeanne-Marie Devaster, et al.
Vaccine|January 25, 2020
Does respiratory syncytial virus lower respiratory illness in early life cause recurrent wheeze of early childhood and asthma? Critical review of the evidence and guidance for future studies from a World Health Organization-sponsored meetingAmanda J Driscoll, S Hasan Arshad, Louis Bont, et al.
The Journal of Infectious Diseases|March 22, 2014
Relative efficacy of AS03-adjuvanted pandemic influenza A(H1N1) vaccine in children: results of a controlled, randomized efficacy trialTerry Nolan, Sumita Roy-Ghanta, May Montellano, et al.
Lancet (London, England)|November 17, 2025
Safety and immunogenicity of a Nipah virus vaccine (HeV-sG-V) in adults: a single-centre, randomised, observer-blind, placebo-controlled, phase 1 studyRobert W Frenck, Abdi Naficy, Jodi Feser, et al.
Pageof 12